Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis

Table 3 Characteristic of patients treated with sorafenib

Variable	Overall (n = 82)	BCLC stage B (n = 36)	BCLC stage C (n = 36)	BCLC stage D (n = 10)	P value
Age, yr (± SD)	63 ± 9	63 ± 8	62 ± 10	63 ± 8	0.86
Male gender, n (%)	68 (82.9)	29 (80.6)	31 (86.1)	8 (80.0)	0.88
Non-cirrhotic liver, n (%)	9 (11.0)	3 (8.3)	5 (13.9)	1 (10.0)	0.78
Etiology, n (%)					0.11
HCV	28 (34.1)	16 (44.4)	11 (30.6)	1 (10.0)
HBV	4 (4.9)	2 (5.6)	1 (2.8)	1 (10.0)
Alcohol	18 (21.9)	9 (25.0)	8 (22.2)	1 (10.0)
NASH	10 (12.2)	4 (11.1)	4 (11.1)	2 (20.0)
Others	22 (26.8)	5 (13.9)	12 (33.3)	5 (50.0)
Child Pugh A/B/C, n (%)	48 (58)/30 (37)/4 (5)	25 (69)/11 (31)/-	21 (58)/15 (42)/-	2 (20)/4 (40)/4 (40)
CSPH1, n (%)	45 (54.9)	21 (58.3)	18 (50.0)	6 (60.0)	0.66
Median nº HCC nodules (IQR)2	2 (1-4)	2 (2-4)	2 (1-4)	1.5 (1-2)	0.25
Median largest HCC diameter, mm, (IQR)2	70 (47-100)	65 (46-90)	87 (48.5-130)	57.5 (39-121)	0.56
Bilobar involvement, n (%)	30 (37.0)	10 (27.8)	18 (50.0)	3 (30.0)	0.33
Diffuse HCC pattern, n (%)	6 (7.4)	2 (5.6)	3 (8.3)	1 (10.0)	0.35
Median AFP, ng/mL (IQR)	103 (7.0-1069)	30 (7.2-739)	150 (6.3-1210)	649 (16-2198)	0.26
AFP > 200 ng/mL, n (%)	35 (43.7)	12 (34.3)	16 (45.7)	7 (70)	0.13
AFP > 400 ng/mL, n (%)	30 (37.5)	10 (28.6)	13 (37.1)	7 (70)	0.06
AFP > 1000 ng/mL, n (%)	21 (25.9)	5 (14.3)	12 (33.3)	4 (40)	0.13
Vascular invasion, n (%)	27 (33.3)	-	25 (69.4)	3 (30.0)	< 0.0001
Extrahepatic disease, n (%)	19 (23.5)	-	18 (50.0)	1 (10.0)	< 0.0001

¹Clinically significant portal hypertension defined as presence of at least one of the following: ascites, gastro-aesophagueal varices or hepatic encephalopathy.

²Intrahepatic nodules. AFP: Alpha-feto protein; TACE: Transarterial chemoembolization; BCLC: Barcelona clinic liver cancer.